Jump to content
We need you! See something you could improve? Make an edit and help improve WikSM for everyone.

High Altitude Pulmonary Edema

From WikiSM
(Redirected from HAPE)


Other Names

  • High Altitude Pulmonary Edema (HAPE)
  • High Altitude Pulmonary Oedema (HAPO)
  • “re-entry” HAPE

Background

History

  • First case English case report by Houston in 1960[1]

Epidemiology

  • It is a relatively rare disease, lacking good epidemiological data
  • Incidence
    • In Peru in the 1970s, estimated to be be 0−6% in adults and 8−9% in children[2]
    • In the early 1980s, estimated to be between 0.01-0.1% in Vail, Colorado[3]
    • Generally thought to represent far less than 1% of all high altitude illness cases (need citation)
    • Incidence increases to 4% to 20% at extreme altitudes (> 5500 m) or extreme rates of ascent (> 600 m/day)[4]

Pathophysiology

  • General
    • HAPE is a pulmonary presentation of acute high altitude illness
    • Onset usually 2–4 days after ascent; rare after 1 week at a constant altitude
    • Most commonly seen above 2500 to 3000 m, less commonly between 1400 and 2400 m[5]
  • Types
    • Most commonly, it occurs in rapid ascension in unacclimatized lowlanders
    • “re-entry” HAPE: rarely, it can occur in inhabitants returning from a trip at "low altitude"

Mechanism

  • Non-cardiogenic Pulmonary edema
    • Alveolar hypoxia causes pulmonary circulation vasoconstriction, subsequent pulmonary hypertension
    • HAPE susceptible individuals have exaggerated pulmonary artery vasoconstriction and pressures with hypoxia or normoxic exercise at sea level[6]
  • Hypoxic pulmonary vasoconstriction
    • Thought to be non-uniform, causing regional overperfusion[7]
    • Endothelial dysfunction may be provoked
    • Impaired nitrous oxide synthesis may confer genetic susceptibility, underlying mechanism
  • Alveolar capillary leak
    • Stress failure secondary to pulmonary artery hypertension
    • Leads to leakage of large molecules into the alveolar space, subsequent high-permeability pulmonary edema
    • Worse/ exacerbated by exercise[8]
  • Impaired clearance of alveolar fluid
    • HAPE susceptible individuals have a defective transepithelial sodium transport in their alveoli
    • Impairment is likely exacerbated at altitude
    • Salmeterol, dexamethasone may improve transepithelial sodium transport[9][10]

Associated Conditions

Risk Factors

Differential Diagnosis

Clinical Features

  • History
    • Early symptoms include exertional dyspnea, dry cough and reduced exercise performance
    • May appear over hours or days, can appear suddenly after a night's sleep at altitude
    • Note that early symptoms are often minimized by individuals but may reflect early HAPE
    • Classic symptoms
      • Dyspnea at rest
      • Cough
      • Decreased exercise tolerance
      • Chest tightness or congestion
    • Other potential symptoms: fatigue, headache, elevated body temperature, generally not exceeding 38.5°C
      • Note that AMS often will overlap
    • Symptoms can worse over time as pulmonary edema progresses
      • Aggravated cough, breathlessness even at rest
  • Physical Exam
    • Classic signs
      • Wheeze on auscultation
      • Central cyanosis
      • Tachypnoea
      • Tachycardia
    • Severe findings include pink frothy sputum, gurgling sounds

Evaluation

Symptom Clinical Signs
Dyspnea at rest Crepitus or wheezing on auscultation
Cough Central cyanosis
Decreased exercise tolerance Tachypnea
Chest tightness Tachycardia
  • Diagnosis is clinical
    • Diagnosis is made by the presence of two clinical symptoms and two clinical signs[12]

Radiographs

  • Chest Radiograph
    • Not required to make diagnosis
  • Findings
    • Peripheral patchy pulmonary oedema in the lower zones, more often right sided
    • Normal cardiac size with prominent pulmonary arteries

Electrocardiogram

  • Not required to make diagnosis
  • Findings[13]
    • Sinus tachycardia
    • Right axis deviation
    • Right bundle branch block or right strain

Laboratory

  • Labs are not required to make the diagnosis
    • Can be useful to confirm, exclude other pathology
  • Blood gas
    • Hypoxemia
    • Respiratory alkalosis

Classification

  • Currently, no classification system exists for HAPE

Management

Prevention

Treatment

  • Sumamry of treatment
    • Increase oxygenation using rapid descent
    • Adjunct: o2 supplementation or portable hyperbaric chamber
    • Adjunct: Nifedipine if oxygen is not available
  • Descent
    • Most effective treatment (as with all forms of AHAI)
    • First line treatment, especially in remote or austere settings
    • Initial descent should be at least 1000 m or until symptms resolve
    • Ideally, with minimal exertion by the patient
  • Hospital
    • Supplementary oxygen
    • Consider positive airway pressure, there are case reports supporting use[15]
    • Consider inhaled nitric oxide
  • Nifedipine
    • Can be used when descent or oxygen not possible
    • Dose: 60 mg modified release divied into 2 or 3 doses (same as prophylaxis)
    • Recommended as a first line adjunct with WMS guidelines
    • However, no benefit if oxygen and descent are available
  • Phosphodiesterase inhibitors
    • Not currently recommended due to increase in AMS severity

Rehab and Return to Play

Rehabilitation

  • Needs to be updated

Return to Play/ Work

  • Little evidence is present to guide team physicians
    • Clinical judgement is paramount
  • Athlete should be completely asymptomatic before considering return
  • Staged ascent is recommended
    • Less than 500 to 600 m/day with rest every 2 days
    • This was effective in one case series to prevent recurrent HAPE in three mountaineers[16]
  • Consider Nifedipine prophylaxis

Complications and Prognosis

Prognosis

  • Death
    • Highest mortality rate of AHAI[17]

Complications

  • Need for hospitalization
  • Death

See Also

References

  1. ↑ Houston CS. Acute pulmonary edema of high altitude. N Engl J Med 1960; 263: 478−80.
  2. ↑ Hultren HN, Marticorena E. High altitude pulmonary edema: epidemiologic observations in Peru. Chest 1978; 74: 372−6.
  3. ↑ Sophocles AM Jr. High-altitude pulmonary edema in Vail, Colorado, 1975–1982. High Alt Med Biol 1986; 144: 569−73.
  4. ↑ Rodway GW, Hoffman LA, Sanders MH. High-altitude related disorders Y part 1: pathophysiology, differential diagnosis, and treatment. Heart Lung. 2003; 33:198.
  5. ↑ Gabry AL, Ledoux X, Mozziconacci M, Martin C. High-altitude pulmonary edema at moderate altitude (<2,400 m; 7,870 feet): a series of 52 patients. Chest 2003; 123: 49−53.
  6. ↑ Hultgren HN, Lopez CE, Lundberg E, Miller H. Physiologic studies of pulmonary edema at high altitude. Circulation 1964; 29: 393–408.
  7. ↑ Hultgren HN. High-altitude pulmonary edema: current concepts. Annu Rev Med 1996; 47: 267–284.
  8. ↑ Eldridge MW, Braun RK, Yoneda KY, Walby WF. Effects of altitude and exercise on pulmonary capillary integrity: evidence for subclinical high-altitude pulmonary edema. J Appl Physiol 2006; 100: 972–980.
  9. ↑ Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006; 145: 497–506.
  10. ↑ Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002; 346: 1631–1636.
  11. ↑ 11.0 11.1 Hultgren HN, Honigman B, Theis K, Nicholas D. High-altitude pulmonary edema at a ski resort. West J Med 1996; 164: 222–227.
  12. ↑ Sutton J, Coates G, Houston C. The Lake Louise consensus on the definition and quantification of altitude illness. Hypoxia and Mountain Medicine. 1992. Burlington, Vermont: Queen City Printers, pp. 327–330.
  13. ↑ Maggiorini M. Prevention and treatment of high-altitude pulmonary edema. Prog Cardiovasc Dis 2010; 52: 500–506.
  14. ↑ Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019
  15. ↑ Larson EB. Positive airway pressure for high-altitude pulmonary oedema. Lancet 1985; 1: 371–373.
  16. ↑ Litch JA, Bishop RA. Reascent following resolution of high altitude pulmonary edema (HAPE). High Alt. Med. Biol. 2001; 2:53Y5.
  17. ↑ Maggiorini M. High altitude-induced pulmonary oedema. Cardiovasc. Res. 2006; 72:41Y50.
Created by:
John Kiel on 30 June 2019 23:00:44
Authors:
Last edited:
24 April 2022 12:37:46
Categories:
Retrieved from "https://wikism.org/w/index.php?title=High_Altitude_Pulmonary_Edema&oldid=16653"